Testing the drug Lutathera in young people whose high-grade brain or spine tumor has come back or grown
Original title: Lutathera for Treatment of Recurrent or Progressive High-Grade CNS Tumors
How far along is this research?
This is a trial that is enrolling or has been updated. It is not a finding yet.
This is an early study, and it is still testing whether the drug is safe in people.
Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.
The trial team last updated this record on . Always check the trial page for the latest.
The short version
This study is testing whether a drug called Lutathera is safe, and whether it helps young people whose brain or spine tumor has come back or is growing.
Who this trial is for. This trial is for young people with a high-grade central nervous system tumor, or a meningioma, that has come back or is growing, and whose tumor shows up on a scan called a DOTATATE PET scan. Phase 1 is for children ages 4 to under 12. Phase 2 is for people ages 12 to 39. The drug, Lutathera, is given through a vein once every 8 weeks, for up to 4 doses over 8 months.
Where it stands. The trial has not reported results. It is measuring how safe the drug is and how well it works against these tumors. Those answers are not in yet.
What this means, and what it doesn't
What it could mean: For now, this is a study, not care your own doctor can give you. If you or your child seems to fit what the study is looking at, you can ask your care team about it. They can tell you whether it makes sense to look into.
What it doesn't mean: This does not mean the drug works. A trial is a test, not a proven treatment. Joining a study is not a guarantee that it will help, and it is not a promise of a cure. It also does not mean anyone is guaranteed a place in the study. The trial team decides who can take part.
Source: ClinicalTrials.gov, July 20, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.